Case Report: Vemurafenib Treatment in Brain Metastases of BRAF(S365L)-Mutant Lung Papillary Cancer by Genetic Sequencing of Cerebrospinal Fluid Circulating Tumor DNA Detection

BRAF mutations, primarily sensitizing mutations, such as BRAF(V600E), have been proven to response to the BRAF inhibitor, Dabrafenib combined with trametinib therapy, but there have been no data demonstrating that it has activity against NSCLC-related brain metastases (BM). How patients harboring BR...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Jianing, Gao, Jinqi, Wang, Gang, Lv, Jinyan, Chen, Wenting, Ben, Jing, Wang, Ruoyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226071/
https://www.ncbi.nlm.nih.gov/pubmed/34178685
http://dx.doi.org/10.3389/fonc.2021.688200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226071/
https://www.ncbi.nlm.nih.gov/pubmed/34178685
http://dx.doi.org/10.3389/fonc.2021.688200

Ejemplares similares